{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:35:03Z","timestamp":1787564103960,"version":"build-2736575974"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11307-026-02082-z","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T19:27:58Z","timestamp":1771442878000},"page":"212-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Theranostic and Radionuclide-based Treatment Approaches for Radioiodine-refractory Thyroid Cancer: From Biology to Clinical Application"],"prefix":"10.1007","volume":"28","author":[{"given":"Mubeen Hussein","family":"Arawker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitrat","family":"Habibullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantanu","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2772-7456","authenticated-orcid":false,"given":"Xinguang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2082_CR1","doi-asserted-by":"crossref","unstructured":"Lesueur F, Truong T (2022) Genetic susceptibility to differentiated thyroid cancer. IntechOpen","DOI":"10.5772\/intechopen.107831"},{"key":"2082_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3389\/fendo.2019.00884","volume":"10","author":"A Matrone","year":"2019","unstructured":"Matrone A, Campopiano MC, Nervo A, Sapuppo G, Tavarelli M, De Leo S (2019) Differentiated thyroid cancer, from active surveillance to advanced therapy: toward a personalized medicine. Front Endocrinol (Lausanne) 10:884","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2082_CR3","first-page":"452","volume":"112","author":"R Paschke","year":"2015","unstructured":"Paschke R, Lincke T, M\u00fcller SP, Kreissl MC, Dralle H, Fassnacht M (2015) The treatment of well-differentiated thyroid carcinoma. Dtsch Arztebl Int 112:452\u2013458","journal-title":"Dtsch Arztebl Int"},{"key":"2082_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1758834014548188","volume":"6","author":"F Worden","year":"2014","unstructured":"Worden F (2014) Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 6:267\u2013279","journal-title":"Ther Adv Med Oncol"},{"key":"2082_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1590\/2359-3997000000245","volume":"61","author":"A Schmidt","year":"2017","unstructured":"Schmidt A, Iglesias L, Klain M, Pitoia F, Schlumberger MJ (2017) Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch Endocrinol Metab 61:81\u201389","journal-title":"Arch Endocrinol Metab"},{"key":"2082_CR6","doi-asserted-by":"publisher","first-page":"175883401775285","DOI":"10.1177\/1758834017752853","volume":"10","author":"L Faugeras","year":"2018","unstructured":"Faugeras L, Pirson AS, Donckier J et al (2018) Refractory thyroid carcinoma: which systemic treatment to use? Ther Adv Med Oncol 10:1758834017752853","journal-title":"Ther Adv Med Oncol"},{"key":"2082_CR7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/cancers11091382","volume":"11","author":"M Aashiq","year":"2019","unstructured":"Aashiq M, Silverman DA, Na\u2019ara S, Takahashi H, Amit M (2019) Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers (Basel) 11:1382","journal-title":"Cancers (Basel)"},{"key":"2082_CR8","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.3390\/curroncol31070286","volume":"31","author":"F Volpe","year":"2024","unstructured":"Volpe F, Nappi C, Zampella E et al (2024) Current advances in radioactive iodine-refractory differentiated thyroid cancer. Curr Oncol 31:3870\u20133884","journal-title":"Curr Oncol"},{"key":"2082_CR9","doi-asserted-by":"publisher","first-page":"12613","DOI":"10.3390\/ijms241612613","volume":"24","author":"SL Rulten","year":"2023","unstructured":"Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM (2023) The future of precision oncology. Int J Mol Sci 24:12613","journal-title":"Int J Mol Sci"},{"key":"2082_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41467-017-00451-5","volume":"8","author":"S Chia","year":"2017","unstructured":"Chia S, Low JL, Zhang X et al (2017) Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun 8:435","journal-title":"Nat Commun"},{"key":"2082_CR11","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.3390\/jcm11144028","volume":"11","author":"C Floridi","year":"2022","unstructured":"Floridi C, Cellina M, Irmici G et al (2022) Precision imaging guidance in the era of precision oncology: an update of imaging tools for interventional procedures. J Clin Med 11:4028","journal-title":"J Clin Med"},{"key":"2082_CR12","first-page":"22","volume":"14","author":"C Cortas","year":"2023","unstructured":"Cortas C, Charalambous H (2023) Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life (Basel) 14:22","journal-title":"Life (Basel)"},{"key":"2082_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-91442-8_13","volume":"211","author":"S Zsch\u00e4bitz","year":"2018","unstructured":"Zsch\u00e4bitz S, Gr\u00fcllich C (2018) Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1\u20133, FGFR 1\u20134, PDGFR\u03b1, KIT and RET. Recent Results Cancer Res 211:187\u2013198","journal-title":"Recent Results Cancer Res"},{"key":"2082_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5306\/wjco.v13.i1.9","volume":"13","author":"F Pitoia","year":"2022","unstructured":"Pitoia F, Jerkovich F, Trimboli P, Smulever A (2022) New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J Clin Oncol 13:9\u201327","journal-title":"World J Clin Oncol"},{"key":"2082_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1186\/s12885-019-6369-7","volume":"19","author":"N Fleeman","year":"2019","unstructured":"Fleeman N, Houten R, Chaplin M et al (2019) A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer 19:1209","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"2082_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cam4.5105","volume":"11","author":"UA Herranz","year":"2022","unstructured":"Herranz UA (2022) Use of multikinase inhibitors\/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer. Cancer Med 11(Suppl 1):47\u201353","journal-title":"Cancer Med"},{"key":"2082_CR17","first-page":"281","volume":"8","author":"S Jasim","year":"2014","unstructured":"Jasim S, Ozsari L, Habra MA (2014) Multikinase inhibitors use in differentiated thyroid carcinoma. Biologics 8:281\u2013291","journal-title":"Biologics"},{"key":"2082_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","volume":"56","author":"RI Haddad","year":"2017","unstructured":"Haddad RI, Schlumberger M, Wirth LJ et al (2017) Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56:121\u2013128","journal-title":"Endocrine"},{"key":"2082_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/thy.2023.0363","volume":"34","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Hu MI, Mansfield AS et al (2024) Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-Altered thyroid cancer: Updated efficacy and safety data from the ARROW Study. Thyroid 34:26\u201340","journal-title":"Thyroid"},{"key":"2082_CR20","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/hed.26527","volume":"43","author":"Y Jozaghi","year":"2021","unstructured":"Jozaghi Y, Zafereo M, Williams MD et al (2021) Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck 43:E7-e12","journal-title":"Head Neck"},{"key":"2082_CR21","doi-asserted-by":"publisher","first-page":"924841","DOI":"10.3389\/fendo.2022.924841","volume":"13","author":"S Satapathy","year":"2022","unstructured":"Satapathy S, Bal C (2022) Theranostic options for radioiodine-refractory differentiated thyroid carcinoma: recent advances, challenges, and road ahead. Front Endocrinol (Lausanne) 13:924841","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2082_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/PPO.0000000000000720","volume":"30","author":"NK Taunk","year":"2024","unstructured":"Taunk NK, Escorcia FE, Lewis JS, Bodei L (2024) Radiopharmaceuticals for cancer diagnosis and therapy: new targets, new therapies-alpha-emitters, novel targets. Cancer J 30:218\u2013223","journal-title":"Cancer J"},{"key":"2082_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12149-025-02090-z","volume":"39","author":"T Watabe","year":"2025","unstructured":"Watabe T, Hirata K, Iima M et al (2025) Recent advances in theranostics and oncology PET: emerging radionuclides and targets. Ann Nucl Med 39:909\u2013921","journal-title":"Ann Nucl Med"},{"key":"2082_CR24","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"Oh JM, Ahn BC (2021) Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11:6251\u20136277","journal-title":"Theranostics"},{"key":"2082_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1530\/ERC-19-0491","volume":"27","author":"C Buffet","year":"2020","unstructured":"Buffet C, Wassermann J, Hecht F et al (2020) Redifferentiation of radioiodine-refractory thyroid cancers. Endocrine-Related Cancer 27:113\u2013132","journal-title":"Endocrine-Related Cancer"},{"key":"2082_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3803\/EnM.2014.29.3.233","volume":"29","author":"J-K Chung","year":"2014","unstructured":"Chung J-K, Cheon GJ (2014) Radioiodine therapy in differentiated thyroid cancer: The first target ed therapy in oncology. Endocrinol Metab 29:233","journal-title":"Endocrinol Metab"},{"key":"2082_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/or.2015.3946","volume":"34","author":"C Yao","year":"2015","unstructured":"Yao C, Pan YI, Li Y et al (2015) Effect of sodium\/iodide symporter (NIS)-mediated radioiodine therapy o n estrogen receptor-negative breast cancer. Oncol Rep 34:59\u201366","journal-title":"Oncol Rep"},{"key":"2082_CR28","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1158\/0008-5472.CAN-09-1077","volume":"69","author":"D Liu","year":"2009","unstructured":"Liu D, Hou P, Liu Z, Wu G, Xing M (2009) Genetic alterations in the phosphoinositide 3-kinase\/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311\u20137319","journal-title":"Cancer Res"},{"key":"2082_CR29","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","volume":"98","author":"I Landa","year":"2013","unstructured":"Landa I, Ganly I, Chan TA et al (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-1566","journal-title":"J Clin Endocrinol Metab"},{"key":"2082_CR30","doi-asserted-by":"publisher","first-page":"e55435","DOI":"10.7554\/eLife.55435","volume":"9","author":"JM Nichols","year":"2020","unstructured":"Nichols JM, Antolovi\u0107 V, Reich JD, Brameyer S, Paschke P, Chubb JR (2020) Cell and molecular transitions during efficient dedifferentiation. Elife 9:e55435","journal-title":"Elife"},{"key":"2082_CR31","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.3390\/jcm13237021","volume":"13","author":"P Petranovi\u0107Ov\u010dari\u010dek","year":"2024","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, Tuncel M, Aghaee A, Campenn\u00ec A, Giovanella L (2024) Redifferentiation therapies in thyroid oncology: molecular and clinical aspects. J Clin Med 13:7021","journal-title":"J Clin Med"},{"key":"2082_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho AL, Grewal RK, Leboeuf R et al (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623\u2013632","journal-title":"N Engl J Med"},{"key":"2082_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4274\/2017.26.suppl.09","volume":"26","author":"SM Larson","year":"2017","unstructured":"Larson SM, Osborne JR, Grewal RK, Tuttle RM (2017) Redifferentiating thyroid cancer: selumetinib-enhanced radioiodine uptake in thyroid cancer. Mol Imaging Radionucl Ther 26:80\u201386","journal-title":"Mol Imaging Radionucl Ther"},{"key":"2082_CR34","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","volume":"29","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux S, Do Cao C, Zerdoud S et al (2023) A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p. V600E-mutated differentiated thyroid cancer. Clin Cancer Res 29:2401\u20132409","journal-title":"Clin Cancer Res"},{"key":"2082_CR35","doi-asserted-by":"crossref","unstructured":"Faria M, Domingues R, Bugalho MJ, Silva AL, Matos P (2021) Analysis of NIS plasma membrane interactors discloses key regulation by a SRC\/RAC1\/PAK1\/PIP5K\/EZRIN pathway with potential implications for radioiodine re-sensitization therapy in thyroid cancer. Cancers (Basel) 13(21):5460","DOI":"10.3390\/cancers13215460"},{"key":"2082_CR36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/diagnostics11081417","volume":"11","author":"C Ferrari","year":"2021","unstructured":"Ferrari C, Santo G, Ruta R et al (2021) Early Predictive response to multi-tyrosine kinase inhibitors in advanced refractory radioactive-iodine differentiated thyroid cancer: A new challenge for [(18)F]FDG PET\/CT. Diagnostics (Basel) 11:1417","journal-title":"Diagnostics (Basel)"},{"key":"2082_CR37","doi-asserted-by":"publisher","first-page":"e44540","DOI":"10.1097\/MD.0000000000044540","volume":"104","author":"LTT Nhung","year":"2025","unstructured":"Nhung LTT, Hoan NX, Giang DP et al (2025) Prognostic significance of BRAF V600E and TERT promoter mutations in radioiodine resistance and recurrence of differentiated thyroid cancer. Medicine (Baltimore) 104:e44540","journal-title":"Medicine (Baltimore)"},{"key":"2082_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2012.08.019","volume":"365","author":"E Lavarone","year":"2013","unstructured":"Lavarone E, Puppin C, Passon N, Filetti S, Russo D, Damante G (2013) The PARP inhibitor PJ34 modifies proliferation, NIS expression and epi genetic marks in thyroid cancer cell lines. Mol Cell Endocrinol 365:1\u201310","journal-title":"Mol Cell Endocrinol"},{"key":"2082_CR39","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1042\/BSR20130134","volume":"34","author":"BM Andrade","year":"2014","unstructured":"Andrade BM, de Carvalho DP (2014) Perspectives of the AMP-activated kinase (AMPK) signalling pathway in thyroid cancer. Biosci Rep 34:e00105","journal-title":"Biosci Rep"},{"key":"2082_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.omto.2019.01.007","volume":"12","author":"H Fu","year":"2019","unstructured":"Fu H, Cheng L, Jin Y, Cheng L, Liu M, Chen L (2019) MAPK inhibitors enhance HDAC inhibitor-induced redifferentiation in papillary thyroid cancer cells harboring BRAF (V600E): an in vitro study. Mol Ther Oncolytics 12:235\u2013245","journal-title":"Mol Ther Oncolytics"},{"key":"2082_CR41","doi-asserted-by":"publisher","first-page":"757","DOI":"10.18203\/2349-2902.isj20210400","volume":"8","author":"P Poolakkil","year":"2012","unstructured":"Poolakkil P, Thavarool SB, Balasubramanyam S, Philip KJ (2012) De-differentiation in thyroid cancer- an increasingly appreciated conc ept. Int Surg J 8:757","journal-title":"Int Surg J"},{"key":"2082_CR42","doi-asserted-by":"publisher","first-page":"1644562","DOI":"10.3389\/fonc.2025.1644562","volume":"15","author":"T Ma","year":"2025","unstructured":"Ma T, Xie Y, Long X, Ye F (2025) High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma. Front Oncol 15:1644562","journal-title":"Front Oncol"},{"key":"2082_CR43","doi-asserted-by":"publisher","first-page":"100492","DOI":"10.1016\/j.coemr.2023.100492","volume":"33","author":"GH Carro","year":"2023","unstructured":"Carro GH, Nicola JP (2023) Molecular mechanisms underlying sodium iodide symporter expression at the plasma membrane in the thyroid follicular cell. Curr Opin Endocr Metab Res 33:100492","journal-title":"Curr Opin Endocr Metab Res"},{"key":"2082_CR44","doi-asserted-by":"publisher","first-page":"134676","DOI":"10.3389\/fendo.2024.1346476","volume":"15","author":"P Chen","year":"2024","unstructured":"Chen P, Yao Y, Tan H, Li J (2024) Systemic treatments for radioiodine-refractory thyroid cancers. Front Endocrinol 15:134676","journal-title":"Front Endocrinol"},{"key":"2082_CR45","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3229","volume":"21","author":"MA Morgan","year":"2015","unstructured":"Morgan MA, Lawrence TS (2015) Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways. Clin Cancer Res 21:2898\u20132904","journal-title":"Clin Cancer Res"},{"key":"2082_CR46","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/genes11091083","volume":"11","author":"SL Santos","year":"2020","unstructured":"Santos SL, Gil MO, Silva NS et al (2020) Micronuclei formation upon radioiodine therapy for well-differentiated thyroid cancer: the influence of DNA repair genes variants. In Genes 11:1083","journal-title":"In Genes"},{"key":"2082_CR47","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/jcm10071455","volume":"10","author":"ES Grassi","year":"2021","unstructured":"Grassi ES, Ghiandai V, Persani L (2021) Thyroid cancer stem-like cells: from microenvironmental niches to therapeutic strategies. J Clin Med 10:1455","journal-title":"J Clin Med"},{"key":"2082_CR48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-025-01684-4","volume":"18","author":"T Shang","year":"2025","unstructured":"Shang T, Jia Z, Li J et al (2025) Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance. J Hematol Oncol 18:32","journal-title":"J Hematol Oncol"},{"key":"2082_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/08820139.2023.2268656","volume":"52","author":"Y Tao","year":"2023","unstructured":"Tao Y, Li P, Feng C, Cao Y (2023) New insights into immune cells and immunotherapy for thyroid cancer. Immunol Invest 52:1039\u20131064","journal-title":"Immunol Invest"},{"key":"2082_CR50","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.2147\/OTT.S140671","volume":"10","author":"A Yordanova","year":"2017","unstructured":"Yordanova A, Eppard E, K\u00fcrpig S et al (2017) Theranostics in nuclear medicine practice. Onco Targets Ther 10:4821\u20134828","journal-title":"Onco Targets Ther"},{"key":"2082_CR51","doi-asserted-by":"publisher","first-page":"e220157","DOI":"10.1148\/rycan.220157","volume":"5","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Bartlett DJ, McGarrah PW et al (2023) A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer 5:e220157","journal-title":"Radiol Imaging Cancer"},{"key":"2082_CR52","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.3390\/cancers15174290","volume":"15","author":"P Petranovi\u0107Ov\u010dari\u010dek","year":"2023","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, Campenni A, de Keizer B et al (2023) Molecular theranostics in radioiodine-refractory differentiated thyroid cancer. Cancers (Basel) 15:4290","journal-title":"Cancers (Basel)"},{"key":"2082_CR53","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/MED.0000000000000740","volume":"29","author":"ME Roseland","year":"2022","unstructured":"Roseland ME, Dewaraja YK, Wong KK (2022) Advanced imaging and theranostics in thyroid cancer. Curr Opin Endocrinol Diabetes Obes 29:456\u2013465","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2082_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12885-021-08257-x","volume":"21","author":"Z Maghsoomi","year":"2021","unstructured":"Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME (2021) Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer 21:579","journal-title":"BMC Cancer"},{"key":"2082_CR55","doi-asserted-by":"publisher","first-page":"825486","DOI":"10.3389\/fnume.2022.825486","volume":"2","author":"N Malan","year":"2022","unstructured":"Malan N, Vangu MD (2022) Normal variants, pitfalls and artifacts in Ga-68 DOTATATE PET\/CT imaging. Front Nucl Med 2:825486","journal-title":"Front Nucl Med"},{"key":"2082_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/ph13030038","volume":"13","author":"U Hennrich","year":"2020","unstructured":"Hennrich U, Bene\u0161ov\u00e1 M (2020) [(68)Ga]Ga-DOTA-TOC: the first FDA-Approved (68)Ga-radiopharmaceutical for PET imaging. Pharmaceuticals (Basel) 13:38","journal-title":"Pharmaceuticals (Basel)"},{"key":"2082_CR57","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","volume":"146","author":"J Zhang","year":"2020","unstructured":"Zhang J, Song Q, Cai L, Xie Y, Chen Y (2020) The efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol 146:1533\u20131543","journal-title":"J Cancer Res Clin Oncol"},{"key":"2082_CR58","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/iep.12024","volume":"94","author":"H Atkinson","year":"2013","unstructured":"Atkinson H, England JA, Rafferty A et al (2013) Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 94:226\u2013229","journal-title":"Int J Exp Pathol"},{"key":"2082_CR59","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.3390\/cancers15174290","volume":"15","author":"P Petranovi\u0107Ov\u010dari\u010dek","year":"2023","unstructured":"Petranovi\u0107Ov\u010dari\u010dek P, Campenni A, de Keizer B et al (2023) Molecular theranostics in radioiodine-refractory differentiated thyroid cancer. In Cancers 15:4290","journal-title":"In Cancers"},{"key":"2082_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17183070","author":"E Perrone","year":"2025","unstructured":"Perrone E, Calcagni ML, Leccisotti L et al (2025) Peptide receptor radionuclide therapy (PRRT) using actinium-225- and Ac-225\/lutetium-177-labeled (TANDEM) somatostatin receptor antagonist DOTA-LM3 in patients with neuroendocrine neoplasm: a retrospective study concerning safety and survival. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17183070","journal-title":"Cancers (Basel)"},{"key":"2082_CR61","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.3390\/ijms241411626","volume":"24","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O (2023) Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci 24:11626","journal-title":"Int J Mol Sci"},{"key":"2082_CR62","doi-asserted-by":"publisher","first-page":"9867","DOI":"10.18632\/oncotarget.23984","volume":"9","author":"B Heitk\u00f6tter","year":"2018","unstructured":"Heitk\u00f6tter B, Steinestel K, Trautmann M et al (2018) Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget 9:9867\u20139874","journal-title":"Oncotarget"},{"key":"2082_CR63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4103\/iju.iju_292_21","volume":"37","author":"G Rohith","year":"2021","unstructured":"Rohith G (2021) VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer. Indian J Urol 37:372\u2013373","journal-title":"Indian J Urol"},{"key":"2082_CR64","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13550-020-0610-x","volume":"10","author":"LH de Vries","year":"2020","unstructured":"de Vries LH, Lodewijk L, Braat A et al (2020) (68)Ga-PSMA PET\/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617. EJNMMI Res 10:18","journal-title":"EJNMMI Res"},{"key":"2082_CR65","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/RLU.0000000000002161","volume":"43","author":"P Verma","year":"2018","unstructured":"Verma P, Malhotra G, Agrawal R, Sonavane S, Meshram V, Asopa RV (2018) Evidence of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET\/CT. Clin Nucl Med 43:e265\u2013e268","journal-title":"Clin Nucl Med"},{"key":"2082_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/RLU.0000000000001454","volume":"42","author":"S L\u00fctje","year":"2017","unstructured":"L\u00fctje S, Gomez B, Cohnen J et al (2017) Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET\/CT. Clin Nucl Med 42:20\u201325","journal-title":"Clin Nucl Med"},{"key":"2082_CR67","doi-asserted-by":"crossref","unstructured":"Serumula W, Pillay V, Hadebe B, Vorster M (2025) Fibroblast activation protein inhibitor (FAPI)-based theranostics. Pharmaceuticals (Basel) 18","DOI":"10.3390\/ph18040522"},{"key":"2082_CR68","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J et al (2020) Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47:1820\u20131832","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2082_CR69","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"S Banihashemian","year":"2024","unstructured":"Banihashemian S, Akbari M, Pirayesh E et al (2024) Feasibility and therapeutic potential of [Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging 52:237\u2013246","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2082_CR70","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","volume":"29","author":"H Fu","year":"2023","unstructured":"Fu H, Huang J, Zhao T et al (2023) Fibroblast activation protein-targeted radioligand therapy with 177Lu. Clinical Cancer Res 29:4740\u20134750","journal-title":"Clinical Cancer Res"},{"key":"2082_CR71","unstructured":"Hope T (2020) Imaging of Solid Tumors Using FAP-2286.\u00a0ClinicalTrials.gov Identifier: NCT04621435"},{"key":"2082_CR72","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","volume":"12","author":"K Hu","year":"2022","unstructured":"Hu K, Li J, Wang L et al (2022) Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts. Acta Pharm Sin B 12:867\u2013875","journal-title":"Acta Pharm Sin B"},{"key":"2082_CR73","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/RLU.0000000000004260","volume":"47","author":"H Fu","year":"2022","unstructured":"Fu H, Huang J, Sun L, Wu H, Chen H (2022) FAP-targeted radionuclide therapy of advanced radioiodine-refractory differentiated thyroid cancer with multiple cycles of 177 Lu-FAPI-46. Clin Nucl Med 47:906\u2013907","journal-title":"Clin Nucl Med"},{"key":"2082_CR74","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1186\/s12967-025-07307-3","volume":"23","author":"M Udinotti","year":"2025","unstructured":"Udinotti M, Siebolts U, Bauer M et al (2025) Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGF\u03b2 axis and immune suppression in aggressive thyroid cancer. J Transl Med 23:1284","journal-title":"J Transl Med"},{"key":"2082_CR75","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.semnuclmed.2024.05.010","volume":"54","author":"RP Baum","year":"2024","unstructured":"Baum RP, Novruzov E, Zhao T et al (2024) Radiomolecular theranostics with fibroblast-activation-protein inhibitors and peptides. Semin Nucl Med 54:537\u2013556","journal-title":"Semin Nucl Med"},{"key":"2082_CR76","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.3390\/cancers17244019","volume":"17","author":"J Maes","year":"2025","unstructured":"Maes J, P\u00f4let B, Kleynhans J et al (2025) Therapeutic applications of fibroblast activation protein (FAP)-binding radiopharmaceuticals: review of opportunities and challenges. Cancers (Basel) 17:4019","journal-title":"Cancers (Basel)"},{"key":"2082_CR77","doi-asserted-by":"publisher","first-page":"20220463","DOI":"10.1259\/bjr.20220463","volume":"96","author":"M Hotta","year":"2023","unstructured":"Hotta M, Rieger AC, Jafarvand MG et al (2023) Non-oncologic incidental uptake on FAPI PET\/CT imaging. Br J Radiol 96:20220463","journal-title":"Br J Radiol"},{"key":"2082_CR78","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B et al (2023) Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging 50:1906\u20131918","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2082_CR79","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/cancers17030425","volume":"17","author":"R Pishdad","year":"2025","unstructured":"Pishdad R, Santhanam P (2025) Current and emerging radiotracers and technologies for detection of advanced differentiated thyroid cancer: a narrative review. Cancers (Basel) 17:425","journal-title":"Cancers (Basel)"},{"key":"2082_CR80","first-page":"3536","volume":"106","author":"R Ciappuccini","year":"2021","unstructured":"Ciappuccini R, Saguet-Rysanek V, Giffard F et al (2021) PSMA expression in differentiated thyroid cancer: association with radioiodine, 18FDG uptake, and patient outcome. J Clin Endocrinol Metab 106:3536\u20133545","journal-title":"J Clin Endocrinol Metab"},{"key":"2082_CR81","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s12149-022-01742-8","volume":"36","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zheng S, Zhang J, Yao S, Miao W (2022) (68)Ga-DOTA-FAPI-04 PET\/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann Nucl Med 36:610\u2013622","journal-title":"Ann Nucl Med"},{"key":"2082_CR82","doi-asserted-by":"publisher","first-page":"1218670","DOI":"10.3389\/fchem.2023.1218670","volume":"11","author":"SC George","year":"2023","unstructured":"George SC, Samuel EJJ (2023) Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry. Front Chem 11:1218670","journal-title":"Front Chem"},{"key":"2082_CR83","unstructured":"Killeen RB, Tafti D\u00a0(2025)\u00a0Neuroendocrine tumor 177Lutetium-dotatate therapy. In: StatPearls. Treasure Island, FL: StatPearls Publishing"},{"key":"2082_CR84","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1097\/RLU.0000000000005728","volume":"50","author":"N Raeisi","year":"2025","unstructured":"Raeisi N, Saber Tanha A, Gozashti MH, Kiamanesh Z, Aryana K (2025) 177Lu-FAPI-2286 therapy in a patient with radio-iodine refractory papillary thyroid carcinoma: a favorable clinical and biochemical response. Clin Nucl Med 50:e315\u2013e316","journal-title":"Clin Nucl Med"},{"key":"2082_CR85","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1507\/endocrj.EJ20-0171","volume":"67","author":"T Oba","year":"2020","unstructured":"Oba T, Chino T, Soma A et al (2020) Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. Endocr J 67:1215\u20131226","journal-title":"Endocr J"},{"key":"2082_CR86","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3389\/fonc.2018.00663","volume":"8","author":"PM Kasi","year":"2018","unstructured":"Kasi PM, Maige CL, Shahjehan F et al (2018) A care process model to deliver (177)Lu-Dotatate peptide receptor radionuclide therapy for patients with neuroendocrine tumors. Front Oncol 8:663","journal-title":"Front Oncol"},{"key":"2082_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics8010016","author":"NP Lenzo","year":"2018","unstructured":"Lenzo NP, Meyrick D, Turner JH (2018) Review of gallium-68 PSMA PET\/CT imaging in the management of prostate cancer. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics8010016","journal-title":"Diagnostics"},{"key":"2082_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.12703\/r\/10-36","volume":"10","author":"SM Jhiang","year":"2021","unstructured":"Jhiang SM, Cheng P, Nabhan FA, Sipos JA, Menq CH (2021) Personalized radioiodine therapy for thyroid cancer patients with known disease. Fac Rev 10:36","journal-title":"Fac Rev"},{"key":"2082_CR89","unstructured":"LuMIERE Study Group (2021) A phase 1\/2, multicenter, open-label, non-randomized study to investigate safety and tolerability, pharmacokinetics, dosimetry, and preliminary activity of 177Lu-FAP-2286 in patients with an advanced solid tumors. ClinicalTrials.gov Identifier: NCT0493961"},{"key":"2082_CR90","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M et al (2023) Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 50:2830\u20132845","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2082_CR91","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/pharmaceutics13050599","volume":"13","author":"S Ahenkorah","year":"2021","unstructured":"Ahenkorah S, Cassells I, Deroose CM et al (2021) Bismuth-213 for targeted radionuclide therapy: from atom to bedside. Pharmaceutics 13:599","journal-title":"Pharmaceutics"},{"key":"2082_CR92","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.3390\/cancers15133493","volume":"15","author":"K Hurley","year":"2023","unstructured":"Hurley K, Cao M, Huang H, Wang Y (2023) Targeted Alpha Therapy (TAT) with single-domain antibodies (Nanobodies). Cancers (Basel) 15:3493","journal-title":"Cancers (Basel)"},{"key":"2082_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A (2021) The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. Nucl Med Biol 98\u201399:30\u201339","journal-title":"Nucl Med Biol"},{"key":"2082_CR94","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/cancers13040779","volume":"13","author":"A Juzeniene","year":"2021","unstructured":"Juzeniene A, Stenberg VY, Bruland \u00d8S, Larsen RH (2021) Preclinical and clinical status of PSMA-Targeted alpha therapy for metastatic castration-resistant prostate cancer. Cancers (Basel) 13:779","journal-title":"Cancers (Basel)"},{"key":"2082_CR95","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13139-021-00713-7","volume":"55","author":"E Mahmoudi","year":"2021","unstructured":"Mahmoudi E, Pirayesh E, Deevband MR, Amoui M, Rad MG, Ghorbani M (2021) Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using (177)Lu-DKFZ-PSMA-617. Nucl Med Mol Imaging 55:237\u2013244","journal-title":"Nucl Med Mol Imaging"},{"key":"2082_CR96","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, AbuQbeitah M, Ayg\u00fcn A et al (2015) Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 42:1976\u20131983","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2082_CR97","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3892\/etm.2024.12514","volume":"27","author":"T Niu","year":"2024","unstructured":"Niu T, Fan M, Lin B, Gao F, Tan B, Du X (2024) Current clinical application of lutetium\u2011177 in solid tumors (Review). Exp Ther Med 27:225","journal-title":"Exp Ther Med"},{"key":"2082_CR98","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","volume":"49","author":"E Lopci","year":"2022","unstructured":"Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A et al (2022) Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on rec ommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatm ents in patients with solid tumors version 10. Euro J Nuclear Med Mol Imaging 49:2323\u20132341","journal-title":"Euro J Nuclear Med Mol Imaging"},{"key":"2082_CR99","doi-asserted-by":"publisher","first-page":"48832","DOI":"10.18632\/oncotarget.9453","volume":"7","author":"F Cheng","year":"2016","unstructured":"Cheng F, Su L, Qian C (2016) Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 7:48832\u201348841","journal-title":"Oncotarget"},{"key":"2082_CR100","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA et al (2024) Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management. Endocr Pathol 35:293\u2013308","journal-title":"Endocr Pathol"},{"key":"2082_CR101","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","volume":"64","author":"O Sartor","year":"2023","unstructured":"Sartor O, Ledet E, Huang M et al (2023) Prediction of resistance to (177)Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers. J Nucl Med 64:1721\u20131725","journal-title":"J Nucl Med"},{"key":"2082_CR102","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441\u2013446","journal-title":"Eur J Cancer"},{"key":"2082_CR103","doi-asserted-by":"publisher","first-page":"110443","DOI":"10.1016\/j.radonc.2024.110443","volume":"199","author":"Y Cao","year":"2024","unstructured":"Cao Y, Sutera P, Silva Mendes W et al (2024) Machine learning predicts conventional imaging metastasis-free surviva l (MFS) for oligometastatic castration-sensitive prostate cancer (omCS PC) using prostate-specific membrane antigen (PSMA) PET radiomics. Radiother Oncol 199:110443","journal-title":"Radiother Oncol"},{"key":"2082_CR104","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.3390\/jcm13216534","volume":"13","author":"O \u00d6zman","year":"2024","unstructured":"\u00d6zman O, Veerman H, Contieri R et al (2024) Staging accuracy and prognostic value of prostate-specific membrane antigen PET\/CT strongly depends on lymph node tumor burden. J Clin Med 13:6534","journal-title":"J Clin Med"},{"key":"2082_CR105","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13014-021-01811-8","volume":"16","author":"MME Vogel","year":"2021","unstructured":"Vogel MME, Dewes S, Sage EK et al (2021) A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. Radiat Oncol 16:82","journal-title":"Radiat Oncol"},{"key":"2082_CR106","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1021\/acsnano.7b07252","volume":"12","author":"EB Ehlerding","year":"2018","unstructured":"Ehlerding EB, Grodzinski P, Cai W, Liu CH (2018) Big potential from small agents: nanoparticles for imaging-based companion diagnostics. ACS Nano 12:2106\u20132121","journal-title":"ACS Nano"},{"key":"2082_CR107","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.2147\/OTT.S140671","volume":"10","author":"A Yordanova","year":"2017","unstructured":"Yordanova A, Eppard E, K\u00fcrpig S et al (2017) Theranostics in nuclear medicine practice. OTT 10:4821\u20134828","journal-title":"OTT"},{"key":"2082_CR108","doi-asserted-by":"publisher","first-page":"1355912","DOI":"10.3389\/fnume.2024.1355912","volume":"4","author":"K Ramonaheng","year":"2024","unstructured":"Ramonaheng K, Qebetu M, Ndlovu H et al (2024) Activity quantification and dosimetry in radiopharmaceutical therapy w ith reference to 177Lutetium. Front Nucl Med 4:1355912","journal-title":"Front Nucl Med"},{"key":"2082_CR109","doi-asserted-by":"publisher","first-page":"99","DOI":"10.18869\/acadpub.ijrr.14.2.99","volume":"14","author":"Y Parlak","year":"2016","unstructured":"Parlak Y, Demir M, Cavdar I et al (2016) Bone marrow radiation dosimetry of high dose 131I treatment in differentiated thyroid carcinoma patients. Int-J-Radiat-Res 14:99","journal-title":"Int-J-Radiat-Res"},{"key":"2082_CR110","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X et al (2021) Fibroblast imaging of hepatic carcinoma with (68)Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging 48:196\u2013203","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02082-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:03:46Z","timestamp":1778511826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02082-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02082-z","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review article does not involve human participants, animal experiments, or patient data requiring institutional ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable. All information presented is derived from previously published studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests related to the content of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}